Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus.
Serum levels of the soluble form of the intercellular adhesion molecule-1 (sICAM-1) have been advocated as a parameter of clinical relevance in determining the activation of the immune system in inflammatory disease(s). We have determined sICAM-1 levels in 46 patients with rheumatoid arthritis (RA), in 53 patients with systemic lupus erythematosus (SLE), and in 82 healthy controls using a commercially available ELISA system. When compared to the healthy controls, sICAM-1 levels of the patients did not differ statistically significantly nor was there any difference between the patient groups. However, there was a strong correlation within the patient groups between sICAM-1 levels and conventional measures of disease activity. Thus, although sICAM-1 may be of theoretical interest with regard to immune activation, our results do not support the view of sICAM-1 providing additional information to the clinical rheumatologist when it is compared to more conventional measures such as acute-phase proteins or clinical activity scores.
Machold
K P
KP
Department of Internal Medicine III, University of Vienna, Austria.
Kiener
H P
HP
Graninger
W
W
Graninger
W B
WB
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood*; D015815:Cell Adhesion Molecules / Q000097:blood*; D003953:Diagnosis-Related Groups; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1; D008137:Longitudinal Studies; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D012720:Severity of Illness Index; D012995:Solubility
D015815:Cell Adhesion Molecules; D018799:Intercellular Adhesion Molecule-1